KRAS and colorectal carcinoma: Notably, PDOs derived from multidrug-refractory patients (previously treated with fluoropyrimidine/irinotecan/oxaliplatin with or without bevacizumab/radiotherapy; Figure S1) remained sensitive to LS-1-2, confirming its translational potential for treatment-resistant KRAS-mutant CRC.